血紅蛋白病治療市場規模、佔有率、成長分析、按類型、按治療類型、按最終用途、按地區 - 行業預測，2024-2031 年

2022 年，血紅素病治療的全球市場規模為 82.8 億美元，從 2023 年的 93.2 億美元成長到 2031 年的 240.9 億美元，預計在預測期內（2024-2031 年）將成長。率為12.6%。

由於鐮狀細胞疾病和地中海貧血等疾病的治療解決方案的進步，全球血紅蛋白疾病治療市場正在經歷強勁成長。這些疾病以血紅蛋白產生的遺傳異常為特徵，正在刺激基因治療、幹細胞移植和新藥物治療等技術創新，以糾正遺傳異常並改善患者預後。不斷加強的研發力道和策略夥伴關係正在加速新治療方法的推出。此外，新興市場意識的提高、政府的支持措施和醫療基礎設施的改善也有助於市場擴張。然而，一些地區面臨的挑戰，例如治療成本上升和獲得先進治療的機會有限，可能會阻礙進展。總體而言，市場有望顯著成長，重點是個人化醫療以滿足患者需求。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2023）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析
• 監管環境
• 專利分析
• 案例研究

血紅素病治療市場規模：按類型

• 市場概況
• 鐮狀細胞性貧血症
  • 鐮狀細胞性貧血
  • 鐮狀血紅素C疾病
  • 鐮狀BETA地中海貧血
• 地中海型貧血
  • α地中海貧血
  • BETA地中海型貧血
• 其他血紅蛋白疾病

血紅素病治療市場規模：依治療類型

• 市場概況
• 輸血
• 鐵螯合療法
• 骨髓移植
• 基因治療
• 藥物治療
  • 羥基尿素
  • L-麩醯胺酸
  • 箱式機器人
  • 克里贊利珠單抗
  • 其他藥品

血紅素病治療市場規模：依最終用途

• 市場概況
• 醫院
• 專科診所
• 門診手術中心
• 研究/學術機構

血紅素病治療市場規模：按地區

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2023）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2021-2023）

主要企業簡介

• Sanofi SA（France）
• Global Blood Therapeutics, Inc.（USA）
• bluebird bio, Inc.（USA）
• Emmaus Life Sciences, Inc.（USA）
• Gamida Cell（Israel）
• Pfizer, Inc.（USA）
• Sangamo Therapeutics, Inc.（USA）
• CRISPR Therapeutics（Switzerland）
• Vertex Pharmaceuticals（USA）
• Novartis AG（Switzerland）
• Celgene Corporation（USA）
• Editas Medicine（USA）
• Bioverativ（USA）
• Protagonist Therapeutics（USA）
• F. Hoffmann-La Roche AG（Switzerland）
• Bristol-Myers Squibb（USA）
• Alnylam Pharmaceuticals（USA）
• Ionis Pharmaceuticals（USA）
• Silence Therapeutics（UK）

結論和建議

Global Hemoglobinopathies Treatment Market size was valued at USD 8.28 billion in 2022 and is poised to grow from USD 9.32 billion in 2023 to USD 24.09 billion by 2031, growing at a CAGR of 12.6% during the forecast period (2024-2031).

The global hemoglobinopathies treatment market is experiencing robust growth, driven by advancements in therapeutic solutions for conditions like sickle cell disease and thalassemia. Characterized by genetic abnormalities in hemoglobin production, these disorders have spurred innovations such as gene therapy, stem cell transplantation, and new drug therapies, aimed at correcting genetic defects and improving patient outcomes. Increasing research and development efforts, along with strategic partnerships, are accelerating the introduction of novel treatments. Additionally, heightened awareness, supportive government initiatives, and enhanced healthcare infrastructure in emerging markets contribute to market expansion. However, challenges like high treatment costs and limited access to advanced therapies in certain regions may hinder progress. Overall, the market is set for significant growth, focusing on personalized medicine to meet patient needs.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hemoglobinopathies Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hemoglobinopathies Treatment Market Segmental Analysis

Global Hemoglobinopathies Treatment Market is segmented by type, treatment type, end-use and region. Based on type, the market is segmented into sickle cell disease, thalassemia and other hemoglobinopathies. Based on treatment type, the market is segmented into blood transfusion, iron chelation therapy, bone marrow transplantation, gene therapy and pharmacotherapy. Based on end-use, the market is segmented into hospitals, specialty clinics, ambulatory surgical centers and research and academic institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hemoglobinopathies Treatment Market

A significant driver of the global hemoglobinopathies treatment market is the growing emphasis on personalized medicine. This approach focuses on customizing treatment plans according to individual patient traits such as genetic profiles, disease severity, and therapeutic responses. Improvements in genetic testing and molecular diagnostics empower healthcare professionals to gain insights into the specific genetic mutations associated with hemoglobinopathies. Consequently, this understanding fosters the creation of targeted therapies and precision medicine strategies that enhance patient outcomes and satisfaction. The shift toward personalized medicine not only increases the effectiveness of existing treatments but also catalyzes the innovation of new therapeutic options tailored to individual needs.

Restraints in the Global Hemoglobinopathies Treatment Market

One of the significant challenges facing the global hemoglobinopathies treatment market is the exorbitant cost associated with advanced therapies. Innovative treatment options, including gene therapy and stem cell transplantation, require intricate procedures, specialized technology, and comprehensive post-treatment care, all of which escalate expenses considerably. This financial burden presents difficulties for both patients and healthcare systems, particularly in areas with limited medical resources and lower-income demographics. As a result, the high costs may restrict the adoption of these cutting-edge therapies, potentially creating inequities in healthcare delivery and outcomes for individuals suffering from hemoglobinopathies. Overcoming this financial barrier is essential to guarantee that all patients have access to effective treatment options.

Market Trends of the Global Hemoglobinopathies Treatment Market

The global hemoglobinopathies treatment market is witnessing a significant trend driven by the increasing focus on gene therapy as a revolutionary treatment modality. This trend is fueled by advancements in genetic engineering technologies, particularly CRISPR/Cas9, which facilitate precise correction of genetic mutations responsible for disorders such as sickle cell disease and thalassemia. As researchers and pharmaceutical companies intensify their efforts in R&D, numerous successful clinical trials and regulatory approvals are bolstering confidence in gene therapy's potential to rectify the underlying causes of these conditions. This shift towards innovative, targeted therapies positions gene therapy at the forefront of hemoglobinopathy treatment strategies, promising improved patient outcomes and a transformative impact on the market landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis
• Case Studies

Global Hemoglobinopathies Treatment Market Size by Type & CAGR (2024-2031)

• Market Overview
• Sickle Cell Disease
  • Sickle Cell Anemia
  • Sickle Hemoglobin-C Disease
  • Sickle Beta-Thalassemia
• Thalassemia
  • Alpha Thalassemia
  • Beta Thalassemia
• Other Hemoglobinopathies

Global Hemoglobinopathies Treatment Market Size by Treatment Type & CAGR (2024-2031)

• Market Overview
• Blood Transfusion
• Iron Chelation Therapy
• Bone Marrow Transplantation
• Gene Therapy
• Pharmacotherapy
  • Hydroxyurea
  • L-Glutamine
  • Voxelotor
  • Crizanlizumab
  • Other Drugs

Global Hemoglobinopathies Treatment Market Size by End-Use & CAGR (2024-2031)

• Market Overview
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Research and Academic Institutes

Global Hemoglobinopathies Treatment Market Size & CAGR (2024-2031)

• North America (Type, Treatment Type, End-Use)
  • USA
  • Canada
• Europe (Type, Treatment Type, End-Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment Type, End-Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment Type, End-Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment Type, End-Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Global Blood Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bluebird bio, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emmaus Life Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gamida Cell (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CRISPR Therapeutics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Editas Medicine (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bioverativ (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Protagonist Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Silence Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations